IGF1R trafficking is modulated by VPS25/ESCRT-II in mice and humans to control skeletal fate commitment

The human body is a marvel of construction, built from a relatively small set of raw materials that must be sorted into the right shapes at the right time. In the developing embryo, a single type of cell acts as a versatile builder, capable of becoming either bone or cartilage. This decision is critical: bone provides the rigid framework for movement, while cartilage offers the flexible cushioning needed for joints and the initial scaffolding for many bones. For a healthy skeleton to form, these cells must listen to a complex chorus of chemical signals that tell them when to harden into bone and when to remain soft as cartilage. If this communication breaks down, the result can be severe birth defects, particularly in the face and skull, where intricate structures must fuse and grow with perfect precision. Scientists have long known that cells receive these instructions through receptors on their surfaces, but the mechanism that ensures these signals are turned off once they have done their job has remained a mystery.

A team of researchers has now uncovered a vital piece of this puzzle, revealing how a specific cellular machine controls the fate of skeletal cells in both mice and humans. They focused on a protein called VPS25, which acts as a quality control manager inside the cell. Its job is to help sort used-up signaling receptors, specifically one that responds to a growth factor known as insulin-like growth factor, and send them to the cell's recycling center to be broken down. The researchers found that when this sorting machine is broken, the receptors get stuck inside the cell, trapped in a state of constant activation. This jam causes the cells to ignore the instructions to become bone and instead default to becoming cartilage. By studying embryos with this defect and cells from human patients with a rare genetic disorder, the team demonstrated that fixing the signal jam can restore the ability of these cells to form bone, offering a new understanding of how skeletal development goes wrong and how it might be corrected.

The story begins with the observation of mouse embryos carrying a specific mutation in the gene that produces the VPS25 protein. These embryos displayed a striking set of physical defects: their snouts were stunted, their lower jaws were underdeveloped, and they often had cleft palates, a condition where the roof of the mouth fails to close. When the researchers examined the bones of these embryos, they found that while the cartilage structures formed normally, the bones were either missing or severely underdeveloped. This suggested that the cells were not failing to grow, but rather were choosing the wrong path. Instead of maturing into the hard, mineralized tissue of bone, they were persisting as cartilage. To understand why, the researchers looked at the molecular signals inside these cells. They discovered that the receptor for insulin-like growth factor, a molecule that normally helps cells grow and differentiate, was accumulating in high amounts inside the mutant cells.

In a healthy cell, when a receptor receives a signal from the outside, it eventually gets pulled inside and sent to a lysosome, a cellular compartment that acts like a trash can, to be degraded. This process ensures that the signal is temporary and controlled. However, in the mutant cells lacking functional VPS25, the researchers found that these receptors were being trapped in late endosomes, which are like holding cells before the final trash can. Because the receptors could not be destroyed, they remained active for far too long, sending a continuous, unregulated signal. This persistent signal acted as a false instruction, convincing the skeletal progenitor cells to commit to a cartilage fate rather than a bone fate. The researchers confirmed this by showing that the mutant cells expressed high levels of genes associated with cartilage and low levels of genes required for bone formation, even when they were placed in an environment designed to encourage bone growth.

To prove that this trapped receptor was the direct cause of the problem, the team turned to a different approach. They treated the mutant cells with a drug that specifically blocks the activity of the insulin-like growth factor receptor. When they did this, the cells stopped behaving like cartilage builders and began to form bone again. The drug effectively silenced the noisy, trapped signal, allowing the cells to hear the correct instructions for their development. This result was significant because it showed that the defect was not a permanent loss of the ability to make bone, but rather a specific disruption of the signaling pathway that could be reversed. The researchers also tested this in living mouse embryos, injecting the drug into pregnant mothers carrying the mutant embryos. The treatment reduced the amount of cartilage and allowed more bone to form, rescuing the skeletal defects to a noticeable degree.

The findings were not limited to mice. The researchers collaborated with medical teams to study primary skin cells from human patients who carry mutations in the same VPS25 gene. These patients suffer from a severe, often fatal condition involving brain and craniofacial abnormalities. When the researchers examined these human cells, they found the exact same problem: the insulin-like growth factor receptors were accumulating in the endosomes and failing to be degraded. Just as in the mouse models, the human cells showed signs of hyperactive signaling. This confirmed that the mechanism discovered in the mice is conserved in humans, meaning the same biological rules apply across species. The study provides a clear mechanistic explanation for why these patients develop such severe skeletal issues, linking a defect in cellular waste management directly to a failure in bone formation.

The research also clarified the specific role of VPS25 in different tissues. By using genetic tools to remove the protein only from the outer layer of cells (the epithelium) or only from the inner layer (the mesenchyme), the team found that the protein is essential in both, but for slightly different reasons. In the inner mesenchymal layer, where the bone and cartilage are actually made, the lack of VPS25 caused the cells to lose their ability to become bone. In the outer epithelial layer, the lack of the protein led to increased cell death and poor tissue growth. This detailed mapping helps explain the complex nature of the defects seen in the embryos, showing that the problem is not just one broken part, but a cascade of failures affecting multiple layers of tissue.

Ultimately, this work reveals a previously unknown connection between the cellular machinery that manages waste and the critical decision-making process of skeletal development. It shows that the proper degradation of signaling receptors is not just about cleaning up the cell, but is a fundamental requirement for determining what kind of tissue a cell will become. By identifying the insulin-like growth factor receptor as a key target of this system, the study opens up new possibilities for understanding and potentially treating congenital skeletal abnormalities. While the research does not yet offer a cure for human patients, it provides a concrete target for future therapies. The ability to pharmacologically block the overactive receptor suggests that it might be possible to intervene in the developmental process to guide cells back onto the correct path, offering hope for the reconstruction of skeletal structures that have gone awry.